VDA Chemicals

Vascular Disrupting Agents (VDAs) represent a distinct class of anticancer therapeutics designed to selectively target and destroy the established vasculature within solid tumors, leading to acute tumor ischemia and subsequent necrosis. Unlike anti-angiogenic agents that prevent the formation of new blood vessels, VDAs act on existing, often structurally and functionally abnormal, tumor blood vessels. These vessels are typically leaky, tortuous, disorganized, and exhibit impaired pericyte coverage, making them more vulnerable to disruption compared to normal, mature vasculature. The primary mechanism of action for most VDAs involves inducing rapid and widespread damage to the endothelial cells lining these tumor vessels, causing vessel collapse, increased permeability, and cessation of blood flow, thereby starving the tumor of oxygen and nutrients. This leads to a rapid and extensive central necrosis of the tumor mass, often leaving a viable rim of tumor cells at the periphery that are closer to normal blood supply. VDAs are primarily investigated for the treatment of solid tumors that rely heavily on an established blood supply for growth and survival. These include a wide range of malignancies such as non-small cell lung cancer, ovarian cancer, prostate cancer, melanoma, anaplastic thyroid cancer, and glioblastoma.

Their ability to induce rapid tumor necrosis makes them particularly attractive for bulky, fast-growing tumors. Despite promising preclinical data, the clinical development of VDAs has faced challenges, and none have yet received broad regulatory approval as monotherapy. Combretastatin A4 phosphate (CA4P, fosbretabulin) is the most extensively studied VDA, having progressed through multiple Phase II and Phase III clinical trials for various cancers, often in combination with chemotherapy or radiotherapy. While CA4P demonstrated some efficacy, particularly in anaplastic thyroid cancer, it did not consistently meet primary endpoints in larger trials for other indications. Other notable VDAs in development include OXi4503 (a prodrug of OXi4P), which is a more potent analogue of CA4P, and various ligand-directed VDAs. Research continues to explore their potential, particularly in combination strategies. VDAs can be broadly classified into two main categories: (1) Microtubule-targeting agents, which are the most common type.

These compounds, such as the combretastatins (e.g., CA4P) and dolastatins, bind to tubulin, disrupting microtubule dynamics in endothelial cells. This leads to changes in cell shape, increased vascular permeability, and ultimately, vessel collapse. (2) Ligand-directed agents, which target specific receptors or markers expressed on tumor endothelial cells, such as tissue factor or endoglin, to deliver a cytotoxic payload or induce a pro-thrombotic effect. Key research tool compounds include various combretastatin derivatives and their prodrugs. Challenges associated with VDAs include the aforementioned 'rim effect,' where the outer rim of the tumor often survives due to proximity to normal vessels, potentially leading to tumor regrowth. Other challenges include systemic toxicity, the development of resistance mechanisms, and the difficulty in accurately assessing VDA efficacy in preclinical models that may not fully recapitulate human tumor vascular complexity. To overcome these limitations, VDAs are almost universally explored in combination with conventional therapies like chemotherapy and radiotherapy, as well as with anti-angiogenic agents or immunotherapies, aiming for synergistic effects and more complete tumor eradication.

The goal is to first disrupt the tumor core, then target the surviving peripheral cells and prevent revascularization.

Vadimezan (DMXAA) targeted cGAS-STING signaling regulation and hepatocyte apoptotic responses
Vadimezan (DMXAA) targeted cGAS-STING signaling regulation and hepatocyte apoptotic responses